Solid Biosciences Inc.
SLDB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SLDB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLDB
Solid Biosciences Inc. (SLDB) is a biotechnology company focused on developing gene therapy candidates for neuromuscular and cardiac diseases, with lead programs in Duchenne muscular dystrophy and other genetic disorders.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.05B
Cash Runway
21.3 moLead Asset
SGT-003 (Phase 1/Phase 2)
Next Catalyst
Phase3_Topline · Jan 1, 2034Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 5 clinical trials · 1 catalyst for Solid Biosciences Inc..
Solid Biosciences Inc. (SLDB) is a biotechnology company focused on developing gene therapy candidates for neuromuscular and cardiac diseases, with lead programs in Duchenne muscular dystrophy and other genetic disorders.
- Lead pipeline includes SGT-003 (Duchenne muscular dystrophy), SGT-212 (Friedreich's ataxia), SGT-501 (cardiac gene therapy), and SGT-601 (limb-girdle muscular dystrophy) [sec · filed 2025-11-03].
- Cash and equivalents of $160.7M as of 2026-06-30, with shareholders' equity of $258.3M [sec].
- Ongoing clinical trials include INSPIRE DUCHENNE, IMPACT DUCHENNE, FALCON, and ARTEMIS [sec_mda · as of 2026-08-06].
- Company expects expenses to increase substantially as it advances clinical development and regulatory activities [sec_mda · as of 2026-08-06].
What works
- Cash position of $160.7M as of 2026-06-30 provides a runway to support ongoing clinical trials and operations [sec].
- Multiple pipeline candidates targeting distinct genetic diseases (Duchenne, Friedreich's ataxia, cardiac, limb-girdle) diversify development risk [sec · filed 2025-11-03].
- Company has a history of advancing programs from preclinical to clinical stages, including SGT-003 and SGT-501 [sec · filed 2025-02-18].
What to weigh
- Company has no approved products and is entirely dependent on clinical success of its pipeline candidates [sec · filed 2025-11-03].
- Expenses are expected to increase substantially, and future capital requirements are uncertain, depending on trial progress and regulatory outcomes [sec_mda · as of 2026-08-06].
- Clinical development risks include potential failure to replicate preclinical results in human trials [sec · filed 2025-02-18].
- Company faces competition and regulatory hurdles from the FDA and other authorities [sec · filed 2025-11-03].
From the filings
Quoted directly from source documents.
Pipeline includes SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs.
“risks associated with the Company's ability to advance SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs, capsid libraries and other enabling technologies”
SEC filings · November 3, 2025
Company expects expenses to increase substantially due to clinical development.
“We expect our expenses to increase substantially in connection with our ongoing development activities related to our Candidates.”
SEC MD&A · August 6, 2026
Ongoing clinical trials include INSPIRE DUCHENNE, IMPACT DUCHENNE, FALCON, and ARTEMIS.
“enroll participants in our INSPIRE DUCHENNE, IMPACT DUCHENNE, FALCON and ARTEMIS trials and advance clinical development of SGT-003, SGT-212 and SGT-501”
SEC MD&A · August 6, 2026
Future capital requirements depend on multiple factors including trial progress and regulatory review.
“Our future capital requirements will depend on many factors, including: • the progress, costs and results of the INSPIRE DUCHENNE, IMPACT DUCHENNE, FALCON and ARTEMIS trials and any future clinical trials of our Candidates; • the costs, timing and outcome of regulatory review of our Candidates”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2034-01-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effica — Topline data from a Phase 3 trial expected, which could provide pivotal efficacy and safety results for a pipeline candidate.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Failure to replicate preclinical results in human trials could halt pipeline progress [sec · filed 2025-02-18].
- Regulatory approval uncertainty — Need for FDA and other regulatory approvals for all candidates, with no guarantee of success [sec · filed 2025-11-03].
- Substantial expense increases — Expenses expected to rise significantly, with uncertain future capital requirements [sec_mda · as of 2026-08-06].
- No approved products — Company has no commercial products and is entirely dependent on pipeline success [sec · filed 2025-11-03].
What to watch
- Progress and data readouts from INSPIRE DUCHENNE, IMPACT DUCHENNE, FALCON, and ARTEMIS trials [sec_mda · as of 2026-08-06].
- Regulatory interactions and potential FDA designations for SGT-003, SGT-212, and SGT-501 [sec · filed 2025-11-03].
- Cash runway and any future capital raises, given expected expense increases [sec_mda · as of 2026-08-06].
- Advancement of preclinical programs and capsid libraries into clinical stages [sec · filed 2025-11-03].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Solid Biosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Solid Biosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
21.3 months
D/E 0.12 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~2681d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
139
Total value held
$676.1M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 23,813,292 | $171.5M |
| ra capital management, l.p. | 9,339,978 | $67.2M |
| janus henderson group plc | 8,021,390 | $57.8M |
| blackrock, inc. | 4,958,354 | $35.7M |
| fmr llc | 3,606,404 | $26.0M |
| deep track capital, lp | 3,565,062 | $25.7M |
| armistice capital, llc | 3,200,000 | $23.0M |
| vanguard capital management llc | 2,674,624 | $19.3M |
| citadel advisors llc | 2,648,200 | $19.1M |
| ameriprise financial inc | 2,438,849 | $17.6M |
Showing top 10 of 139 institutional holders of Solid Biosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 11.7%
- Days to cover
- 5.8
- Shares short
- 10,049,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLDB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Solid Biosciences Inc.?
Solid Biosciences Inc. (SLDB) is a biotechnology company focused on developing gene therapy candidates for neuromuscular and cardiac diseases, with lead programs in Duchenne muscular dystrophy and other genetic disorders.
What is Solid Biosciences Inc.'s lead drug candidate?
Solid Biosciences Inc.'s most advanced tracked candidate is SGT-003 (Phase 1/Phase 2) for Duchenne Muscular Dystrophy.
What is Solid Biosciences Inc.'s next catalyst?
Solid Biosciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effica" — expected January 1, 2034.
Who is the CEO of Solid Biosciences Inc.?
Mr. Alexander G. Cumbo is the chief executive officer of Solid Biosciences Inc. (SLDB).
Where is Solid Biosciences Inc. headquartered?
Solid Biosciences Inc. (SLDB) is headquartered in Charlestown, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.